Buscar
OKYO Pharma Ltd
OKYOAñadir a la lista de seguimiento
1.560USD
+0.040+2.63%
Cierre 08-17 16:00（ET）Cotizaciones retrasadas 15 min
79.77MCap. mercado
PérdidaP/E TTM
Más Datos de OKYO Pharma Ltd Compañía
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Perfil de OKYO Pharma Ltd
Símbolo de cotizaciónOKYO
Nombre de la empresaOKYO Pharma Ltd
Fecha de salida a bolsaJul 17, 2018
Director ejecutivoJacob (Gary S)
Número de empleados4
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 17
DirecciónFloor 4, 14/15 Conduit St
CiudadLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW1S 2XJ
Teléfono442074952379
Sitio Webhttps://okyopharma.com/
Símbolo de cotizaciónOKYO
Fecha de salida a bolsaJul 17, 2018
Director ejecutivoJacob (Gary S)
Ejecutivos de OKYO Pharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Senior Non-Executive Director
Senior Non-Executive Director
--
-100.00%
Mr. Bernard F. Denoyer, CPA
Mr. Bernard F. Denoyer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de OKYO Pharma Ltd?
Los cinco principales accionistas de OKYO Pharma Ltd son: Dr. Raj Patil
¿Cuántas instituciones poseen acciones de OKYO Pharma Ltd (OKYO)?
A fecha de 2026Q1, 19 instituciones poseen acciones de OKYO Pharma Ltd, con un valor de mercado combinado de aproximadamente 4.78M, lo que representa el 9.11% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1185385.00.